109). Given the link between CDH2, mTOR and EMT all of which play an important role in cancer biology (the role of EMT in non-epithelial cancers such as leukaemia is an emerging concept (Ref. 110)), including niche-driven leukaemia cell behaviour, combining a CDH2 antagonist with mTOR inhibitors may have a potential therapeutic benefit. The gene discussed is MTOR; the disease is cancer.